Ophthalmic Therapeutic Drugs: Technologies and Global Markets

May 07, 2010

Wellesley, Mass. – According to a new technical market research report, OPHTHALMIC THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM031C) from BCC Research (www.bccresearch.com), the value of the market for ophthalmic therapeutic drugs was an estimated $15.5 billion in 2009, but is expected to increase to nearly $20.1 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 5.9%.

The largest segment of the market, anti-glaucoma drugs, is projected to increase at a CAGR of 3.6% to $6.6 billion in 2014, after being valued at an estimated $5.8 billion in 2009.

Revenues for disease treatments for wet age-related macular degeneration, which make up the second-largest segment, are estimated at more than $2.4 billion in 2009, and are expected to increase at a CAGR of 10% to reach nearly $4 billion in 2014.

The third-largest segment, dry-eye disease therapeutics, is expected to have a 5-year CAGR of 8.4%, with values of nearly $1.9 billion in 2009 and $2.8 billion in 2014.

The segment made up of anti-infectives is projected to have a CAGR of 9.5%, rising from more than $1.3 billion in 2009 to $2.1 billion in 2014.

Annual growth rates in the ophthalmic sector are twice that of the overall pharmaceutical industry, driven by new developments in ophthalmic therapies that have emerged during the past 5 years. These advancements have transformed this historically slow-growth, generic-centric, and price-competitive market segment into a high-growth sector fueled by technology and characterized by increasing opportunity. 

Market growth has been spurred by the introduction of differentiated therapies due to novel mechanism of action, such as ranibizumab, a vascular endothelial growth factor (VEGF) inhibitor that ameliorates the progression of age-related macular degeneration. Ranibizumab is now the single-largest revenue generator in the ophthalmic segment, despite its introduction only a few years ago.

This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants, and anyone interested in the ophthalmic market, its products, its industry participants, and its future.

Ophthalmic Therapeutic Drugs: Technologies and Global Markets ( PHM031C )
Publish Date: Apr 2010    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.